Physician profile
Lisa A Young
NPI 1487642559
$6,813.57
in general payments reported to CMS, 2019-2025
22 companies · $1,595 in 2025
The $1,595 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,383 · 2022: $1,832 · 2023: $1,312 · 2024: $692 · 2025: $1,595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,598.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,796.35 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $827.12 | 2021-2025 | Caplyta |
| Alkermes, INC. | $820.63 | 2021-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $675.11 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $544.07 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $541.03 | 2021-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $311.83 | 2022-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $223.33 | 2022-2025 | Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $199.81 | 2021-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $178.32 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $162.93 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $132.09 | 2022-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $76.10 | 2023-2025 | Auvelity |
| Harmony Biosciences LLC | $73.68 | 2022-2025 | |
| Ironshore Pharmaceuticals INC. | $72.80 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $55.25 | 2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $27.51 | 2021-2022 | |
| Indivior INC. | $25.91 | 2021-2023 | Perseris |
| Neos Therapeutics, LP | $18.48 | 2022 | |
| Corium, LLC | $17.72 | 2022 | |
| Bausch Health US, LLC | $17.72 | 2021 | |
| Collegium Pharmaceutical, INC. | $15.78 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.